Provectus Biopharmaceuticals Inc Share Price Nyse
Equities
US74373P1084
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2022 | 0.99 78.96 | Sales 2023 | 0.56 44.53 | Capitalization | 40.27M 3.22B |
---|---|---|---|---|---|
Net income 2022 | -3M -240M | Net income 2023 | -3M -240M | EV / Sales 2022 | 48,121,944 x |
Net Debt 2022 | 2.16M 173M | Net Debt 2023 | 2.95M 235M | EV / Sales 2023 | 77,502,175 x |
P/E ratio 2022 |
-12.8
x | P/E ratio 2023 |
-13
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.58% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Pershing
CEO | Chief Executive Officer | 71 | 26/04/18 |
Eric A. Wachter
FOU | Founder | 61 | 31/12/01 |
Heather Raines
DFI | Director of Finance/CFO | 58 | 31/07/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric A. Wachter
FOU | Founder | 61 | 31/12/01 |
John W. Lacey
BRD | Director/Board Member | 76 | 26/04/18 |
President | 55 | 02/04/17 |
1st Jan change | Capi. | |
---|---|---|
+3.27% | 108B | |
+10.37% | 105B | |
+1.57% | 23.46B | |
-12.83% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-7.41% | 17.19B | |
+5.88% | 13.99B | |
+36.79% | 12.53B |